Fenfluramine: A Review in Dravet and Lennox-Gastaut Syndromes.
Journal
Drugs
ISSN: 1179-1950
Titre abrégé: Drugs
Pays: New Zealand
ID NLM: 7600076
Informations de publication
Date de publication:
Jul 2023
Jul 2023
Historique:
accepted:
18
04
2023
medline:
23
6
2023
pubmed:
15
6
2023
entrez:
14
6
2023
Statut:
ppublish
Résumé
Fenfluramine (Fintepla Emerging in infancy and childhood, respectively, Dravet syndrome (DS) and Lennox-Gastaut syndrome (LGS) are severe developmental and epileptic encephalopathies. They are characterized by seizures that are frequently ‘pharmacoresistant’ [i.e. cannot be controlled by ≥ 2 anti-seizure medications (ASMs)] and that, along with cognitive and behavioural comorbidities, can have a major impact on the quality of life of patients (and their caregivers/family members) as they grow. Fenfluramine (Fintepla
Autres résumés
Type: plain-language-summary
(eng)
Emerging in infancy and childhood, respectively, Dravet syndrome (DS) and Lennox-Gastaut syndrome (LGS) are severe developmental and epileptic encephalopathies. They are characterized by seizures that are frequently ‘pharmacoresistant’ [i.e. cannot be controlled by ≥ 2 anti-seizure medications (ASMs)] and that, along with cognitive and behavioural comorbidities, can have a major impact on the quality of life of patients (and their caregivers/family members) as they grow. Fenfluramine (Fintepla
Identifiants
pubmed: 37316680
doi: 10.1007/s40265-023-01881-w
pii: 10.1007/s40265-023-01881-w
pmc: PMC10310619
doi:
Substances chimiques
Fenfluramine
2DS058H2CF
Anticonvulsants
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
923-934Commentaires et corrections
Type : ErratumIn
Informations de copyright
© 2023. The Author(s), under exclusive licence to Springer Nature Switzerland AG.
Références
Oncotarget. 2018 May 4;9(34):23373-23389
pubmed: 29805740
Epilepsia. 2000 Aug;41(8):925-8
pubmed: 10961615
Clin Ther. 2018 Aug;40(8):1338-1346
pubmed: 29941151
CNS Drugs. 2021 Jan;35(1):61-83
pubmed: 33479851
Epilepsia. 2022 Jul;63(7):1761-1777
pubmed: 35490361
Eur J Paediatr Neurol. 2022 Jul;39:35-39
pubmed: 35640431
CNS Drugs. 2022 Mar;36(3):217-237
pubmed: 35156171
JAMA Neurol. 2022 Jun 1;79(6):554-564
pubmed: 35499850
Neuropharmacology. 2020 May 15;168:107966
pubmed: 32120063
Int J Mol Sci. 2021 Aug 05;22(16):
pubmed: 34445144
Neurochem Res. 2021 Sep;46(9):2249-2261
pubmed: 34041623
Epilepsia. 2021 Oct;62(10):2518-2527
pubmed: 34378197
Epilepsy Behav. 2021 Sep;122:108212
pubmed: 34352670
Epilepsy Behav. 2022 Feb;127:108526
pubmed: 35007961
Epilepsia. 2022 Jan;63(1):130-138
pubmed: 34676542
Seizure. 2021 Dec;93:154-159
pubmed: 34768178
Int J Clin Pharmacol Ther. 2019 Jan;57(1):11-19
pubmed: 30336805
Neuropediatrics. 2020 Apr;51(2):135-145
pubmed: 32079034
Epilepsia. 2020 Nov;61(11):2396-2404
pubmed: 33078386
Epilepsy Behav. 2021 Aug;121(Pt A):108024
pubmed: 34023810
Epilepsia Open. 2022 Jun;7(2):231-246
pubmed: 35075810
Epilepsia. 2020 Nov;61(11):2386-2395
pubmed: 32809271
Lancet. 2020 Dec 21;394(10216):2243-2254
pubmed: 31862249
Epilepsy Res. 2022 Sep;185:106976
pubmed: 35843016
Front Pharmacol. 2017 Apr 06;8:191
pubmed: 28428755
Epilepsy Behav. 2023 Jan;138:108994
pubmed: 36463826
JAMA Neurol. 2020 Mar 1;77(3):300-308
pubmed: 31790543
Pharmacol Biochem Behav. 1988 Jul;30(3):715-21
pubmed: 2463643
Epilepsia Open. 2022 Dec;7(4):578-587
pubmed: 35801621
Epilepsy Res. 2021 Nov;177:106777
pubmed: 34601387
Expert Rev Neurother. 2022 May;22(5):351-364
pubmed: 33455486
Epilepsia. 2020 Nov;61(11):2405-2414
pubmed: 32945537
Children (Basel). 2022 Aug 02;9(8):
pubmed: 36010049
Pharmacol Ther. 2021 Oct;226:107866
pubmed: 33895186
Acta Neurol Scand. 2019 Mar;139(3):220-230
pubmed: 30443951
Epilepsia. 2018 Oct;59(10):1881-1888
pubmed: 30146701
Epilepsia. 2023 Jan;64(1):139-151
pubmed: 36196777
Eur J Paediatr Neurol. 2021 Mar;31:10-14
pubmed: 33540241
Curr Med Res Opin. 2017 Oct;33(10):1773-1781
pubmed: 28704161
Seizure. 2021 Oct;91:316-324
pubmed: 34274891
Pharmacoeconomics. 2023 Jan;41(1):33-42
pubmed: 36301414